All In Biotech

Drug Trial Radar · NCT02627274

A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

An Open-Label, Multicenter, Dose-Escalation, Phase Ia/Ib Study to Evaluate Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-α (FAP), as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

Last checked: Nov 19, 2026Latest source record: Nov 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

134

Actual

Start

Dec 7, 2015

Primary completion

Nov 10, 2022

Study completion Nov 10, 2022

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 10, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This first-in-human, open-label, multicenter, Phase Ia/Ib, adaptive, multiple ascending-dose study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of RO6874281 as a single agent (Part A) or in combination with trastuzumab or cetuximab (Part B or C).

Conditions

  • Solid Tumor
  • Breast Cancer
  • Cancer of Head and Neck

Interventions

  • RO6874281Drug

    RO6874281 will be administered as per the schedule specified under arm description.

  • TrastuzumabDrug

    Trastuzumab will be administered as per the schedule specified under arm description.

  • CetuximabDrug

    Cetuximab will be administered as per the schedule specified under arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Dose-Limiting Toxicities (DLTs)Time frame: Day 1 up to Day 21
  2. Maximum Tolerated Dose (MTD) of RO6874281Time frame: Day 1 up to Day 21
  3. Optimal Biological Dose (OBD) of RO6874281Time frame: Day 1 up to Day 21
  4. Recommended Dose for Further Development of RO6874281Time frame: Day 1 up to Day 21
  5. Systemic Clearance (CL) of RO6874281Time frame: Day 1 up to 24 months
  6. Volume of Distribution at Steady State (Vss) of RO6874281Time frame: Day 1 up to 24 months
  7. Area Under the Concentration-Time Curve (AUC) of RO6874281Time frame: Day 1 up to 24 months
  8. Maximum Observed Serum Concentration (Cmax) of RO6874281Time frame: Day 1 up to 24 months

Locations

26 sites in 9 countries. Site status is shown where the registry gives one.

  • University of Arizona Cancer Center

    Tucson, Arizona

  • UCSD - Moores Cancer Center

    La Jolla, California

  • Banner MD Anderson Cancer Center

    Greeley, Colorado

  • Washington University; Division of Oncology

    St Louis, Missouri

  • The Ohio State University

    Columbus, Ohio

  • UZ Antwerpen

    Edegem, Belgium

  • Juravinski Cancer Clinic; Department of Oncology

    Hamilton, Ontario, Canada

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada

  • Rigshospitalet; Onkologisk Klinik

    København Ø, Denmark

  • Institut Bergonie; Oncologie

    Bordeaux, France

  • Centre Georges Francois Leclerc

    Dijon, France

  • Centre Leon Berard

    Lyon, France

  • Institut Claudius Regaud; Departement Oncologie Medicale

    Toulouse, France

  • Institut Gustave Roussy; Sitep

    Villejuif, France

  • IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica

    Meldola, Emilia-Romagna, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori;S.S. Trattamento MedicoTumori dellaTesta e delCollo

    Milan, Lombardy, Italy

  • Istituto Europeo di Oncologia; Svil. Nuovi Farmaci per Terapie Innovative

    Milan, Lombardy, Italy

  • Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda); Oncologico -Onc.Falck

    Milan, Lombardy, Italy

  • Ospedale Policlinico S. Matteo; Phase I Clinical Trial Unit and Experimental Therapy

    Pavia, Lombardy, Italy

  • Antoni Van Leeuwenhoek Ziekenhuis; Gastro-Enterologie

    Amsterdam, Netherlands

  • Erasmus MC

    Rotterdam, Netherlands

  • Hospital Univ Vall d'Hebron; Servicio de Oncologia

    Barcelona, Spain

  • Clinica Universitaria de Navarra

    Pamplona, Navarre, Spain

  • Leicester Royal Infirmary

    Leicester, United Kingdom

  • Guys and St Thomas NHS Foundation Trust, Guys Hospital

    London, United Kingdom

  • Christie Hospital

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.